TapewireFind a company

person · Reporting owner

HUGIN ROBERT J

Disclosed activity across 7 companies

Tapewire entity
16186
SEC CIK
0001232505

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Biohaven Ltd.BHVN · Entity 4379DirectorApril 28, 2026May 01, 2026
Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269DirectorOctober 03, 2022October 03, 2022
CELGENE CORP /DE/CELG · Entity 15781Director · see remarksDecember 31, 2017January 31, 2018
Chubb LtdCB · Entity 1639DirectorMay 21, 2026May 26, 2026
DANAHER CORP /DE/DHR · Entity 2871DirectorMay 15, 2017May 17, 2017
MEDICINES CO /DEMDCO · Entity 152552DirectorNovember 09, 2017November 13, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Biohaven Ltd.

Report date April 28, 2026 · Filed May 01, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2036-04-28Direct68,693 Reported balance After 2026-04-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-04-28 · Grant · Acquired 68,693 · Balance 68,693

F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Biohaven Pharmaceutical Holding Co Ltd.

Report date October 03, 2022 · Filed October 03, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeDirect0 Reported balance After 2022-10-03 transaction · row 1
1 source row

Row 1 · 2022-10-03 · Disposition to issuer · Disposed 2,900 · Balance 0

F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").

Restricted Share Unit AwardSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-10-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2022-10-03 · Disposition to issuer · Disposed 3,417 · Balance 0

F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.33 · Expires 2032-04-28Direct0 Reported balance After 2022-10-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2022-10-03 · Disposition to issuer · Disposed 8,239 · Balance 0

F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.17 · Expires 2031-05-05Direct0 Reported balance After 2022-10-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2022-10-03 · Disposition to issuer · Disposed 11,996 · Balance 0

F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.88 · Expires 2030-06-09Direct0 Reported balance After 2022-10-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2022-10-03 · Disposition to issuer · Disposed 18,948 · Balance 0

F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").

F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

CELGENE CORP /DE/

Report date December 31, 2017 · Filed January 31, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,015,106 Reported balance After 2017-09-07 transaction · row 1
1 source row

Row 1 · 2017-09-07 · Gift · Disposed 45,000 · Balance 1,015,106

F1: Gift to a family foundation of which Mr. Hugin is a trustee, but he is not deemed to hold a pecuniary interest in the foundation.

Common StockSEC Table I · non-derivativeIndirectBy Children9,600 Reported balance Holding disclosure · report date 2017-12-31 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 9,600

F2: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirect401(k) Plan641 Reported balance Holding disclosure · report date 2017-12-31 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 641

Filing footnotes · ownership attribution and instrument terms

F1: Gift to a family foundation of which Mr. Hugin is a trustee, but he is not deemed to hold a pecuniary interest in the foundation.

F2: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Chubb Ltd

Report date May 21, 2026 · Filed May 26, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeDirect21,626 Reported balance After 2026-05-21 transaction · row 1
1 source row

Row 1 · 2026-05-21 · Grant · Acquired 1,135 · Balance 21,626

F1: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.

Common SharesSEC Table I · non-derivativeIndirectBy Son225 Reported balance Holding disclosure · report date 2026-05-21 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 225

F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Common SharesSEC Table I · non-derivativeIndirectBy Son110 Reported balance Holding disclosure · report date 2026-05-21 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 110

F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.

F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

DANAHER CORP /DE/

Report date May 15, 2017 · Filed May 17, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect3,576 Reported balance After 2017-05-15 transaction · row 1
1 source row

Row 1 · 2017-05-15 · Grant · Acquired 990 · Balance 3,576

F1: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The RSUs vest on the earlier of the first anniversary of the grant date, or the date of (and immediately prior to) the next annual meeting of Danaher's shareholders following the grant date, but the underlying shares are not issued until the earlier of the director's death or the first day of the seventh month following the director's retirement from the Board.

Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $83.28 · Expires 2027-05-15Direct3,540 Reported balance After 2017-05-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2017-05-15 · Grant · Acquired 3,540 · Balance 3,540

Filing footnotes · ownership attribution and instrument terms

F1: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The RSUs vest on the earlier of the first anniversary of the grant date, or the date of (and immediately prior to) the next annual meeting of Danaher's shareholders following the grant date, but the underlying shares are not issued until the earlier of the director's death or the first day of the seventh month following the director's retirement from the Board.

MEDICINES CO /DE

Report date November 09, 2017 · Filed November 13, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect163,431 Ending reported balance After 2017-11-09 transaction · row 5
5 source rows · reconciled sequence

Row 1 · 2017-11-09 · Exercise / conversion · Acquired 7,500 · Balance 123,133

Row 2 · 2017-11-09 · Exercise / conversion · Acquired 7,500 · Balance 130,633

Row 3 · 2017-11-09 · Exercise / conversion · Acquired 7,500 · Balance 138,133

Row 4 · 2017-11-09 · Exercise / conversion · Acquired 13,259 · Balance 151,392

Row 5 · 2017-11-09 · Exercise / conversion · Acquired 12,039 · Balance 163,431

Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.30 · Expires 2018-05-29Direct0 Reported balance After 2017-11-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2017-11-09 · Exercise / conversion · Disposed 7,500 · Balance 0

F6: Not applicable

F1: This option vested in twelve equal monthly installments beginning on June 29, 2008.

Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.51 · Expires 2019-05-28Direct0 Reported balance After 2017-11-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2017-11-09 · Exercise / conversion · Disposed 7,500 · Balance 0

F6: Not applicable

F2: This option vested in twelve equal monthly installments beginning on June 28, 2009.

Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.28 · Expires 2020-06-02Direct0 Reported balance After 2017-11-09 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2017-11-09 · Exercise / conversion · Disposed 7,500 · Balance 0

F6: Not applicable

F3: This option vested in twelve equal monthly installments beginning on July 2, 2010.

Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.18 · Expires 2021-05-26Direct0 Reported balance After 2017-11-09 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2017-11-09 · Exercise / conversion · Disposed 13,259 · Balance 0

F6: Not applicable

F4: This option vested in one installment beginning on June 26, 2011.

Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.14 · Expires 2022-05-22Direct0 Reported balance After 2017-11-09 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2017-11-09 · Exercise / conversion · Disposed 12,039 · Balance 0

F6: Not applicable

F5: This option vested in one installment beginning on June 22, 2012.

Filing footnotes · ownership attribution and instrument terms

F1: This option vested in twelve equal monthly installments beginning on June 29, 2008.

F2: This option vested in twelve equal monthly installments beginning on June 28, 2009.

F3: This option vested in twelve equal monthly installments beginning on July 2, 2010.

F4: This option vested in one installment beginning on June 26, 2011.

F5: This option vested in one installment beginning on June 22, 2012.

F6: Not applicable

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Allergan plc

Report date May 08, 2020 · Filed May 12, 2020

Section 16 reporting ended · disclosed 2020-05-12. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary Shares, par value $0.0001SEC Table I · non-derivativeDirect0 Reported balance After 2020-05-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2020-05-08 · Disposition to issuer · Disposed 4,294 · Balance 0

F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 21, 2026 Filed May 26, 2026 20:20 UTC Chubb Ltd CB · Entity 1639 GrantCommon Shares 1,135 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-239385 · ownership.xml · nonDerivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,626

F1 · kind: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.

F1 · price: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.

Read SEC document
April 28, 2026 Filed May 1, 2026 00:07 UTC Biohaven Ltd. BHVN · Entity 4379 GrantStock Options (Right to buy) · Derivative 68,693 $0.00 Strike: $9.61 $0.00
Disclosure

SEC source: 0001232505-26-000003 · wk-form4_1777594053.xml · derivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,693

Underlying: Common Shares · 68,693 shares

Expires 2036-04-28

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Read SEC document
May 15, 2025 Filed May 16, 2025 22:51 UTC Chubb Ltd CB · Entity 1639 GrantCommon Shares 1,284 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-25-045003 · ownership.xml · nonDerivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,491

F1 · kind: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.

F1 · price: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.

Read SEC document
May 05, 2025 Filed May 7, 2025 21:11 UTC Biohaven Ltd. BHVN · Entity 4379 GrantStock Options (Right to buy) · Derivative 31,716 $0.00 Strike: $22.62 $0.00
Disclosure

SEC source: 0001935979-25-000041 · wk-form4_1746652311.xml · derivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,716

Underlying: Common Shares · 31,716 shares

Expires 2035-05-05

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 5, 2026 or (b) the date of the 2026 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Read SEC document
May 16, 2024 Filed May 17, 2024 16:53 UTC Chubb Ltd CB · Entity 1639 GrantCommon Shares 1,227 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-24-044606 · marketforms-65942.xml · nonDerivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,207

F1 · kind: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan, which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.

F1 · price: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan, which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.

Read SEC document
April 30, 2024 Filed May 2, 2024 23:33 UTC Biohaven Ltd. BHVN · Entity 4379 GrantStock Option (Right to Buy) · Derivative 16,592 $0.00 Strike: $38.80 $0.00
Disclosure

SEC source: 0001562180-24-003752 · primarydocument.xml · derivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,592

Underlying: Common Shares · 16,592 shares

Expires 2034-04-30

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2025 or (b) the date of the 2025 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Read SEC document
May 17, 2023 Filed May 19, 2023 14:00 UTC Chubb Ltd CB · Entity 1639 GrantCommon Shares 1,634 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-030878 · doc4.xml · nonDerivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,980

F1 · kind: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan, which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.

F1 · price: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan, which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.

Read SEC document
May 02, 2023 Filed May 4, 2023 21:51 UTC Biohaven Ltd. BHVN · Entity 4379 GrantStock Option (Right to Buy) · Derivative 52,906 $0.00 Strike: $13.20 $0.00
Disclosure

SEC source: 0001562180-23-003940 · primarydocument.xml · derivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,906

Underlying: Common Shares · 52,906 shares

Expires 2033-05-02

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 2, 2024 or (b) the date of the 2024 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Read SEC document
October 03, 2022 Filed Oct 3, 2022 20:25 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 Disposition to issuerStock Options (Right to Buy) · Derivative 18,948 Not disclosed Strike: $66.88 Not disclosed
Disclosure

SEC source: 0001562180-22-006961 · primarydocument.xml · derivative · entry 5

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 18,948 shares

Expires 2030-06-09

F4 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Read SEC document
October 03, 2022 Filed Oct 3, 2022 20:25 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 Disposition to issuerStock Options (Right to Buy) · Derivative 11,996 Not disclosed Strike: $70.17 Not disclosed
Disclosure

SEC source: 0001562180-22-006961 · primarydocument.xml · derivative · entry 4

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 11,996 shares

Expires 2031-05-05

F4 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Read SEC document
October 03, 2022 Filed Oct 3, 2022 20:25 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 Disposition to issuerStock Options (Right to Buy) · Derivative 8,239 Not disclosed Strike: $95.33 Not disclosed
Disclosure

SEC source: 0001562180-22-006961 · primarydocument.xml · derivative · entry 3

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 8,239 shares

Expires 2032-04-28

F4 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Read SEC document
October 03, 2022 Filed Oct 3, 2022 20:25 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 Disposition to issuerRestricted Share Unit Award · Derivative 3,417 Not disclosed Not disclosed
Disclosure

SEC source: 0001562180-22-006961 · primarydocument.xml · derivative · entry 2

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 3,417 shares

Expires not disclosed

F1 · derivative.exercise_price: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

F3 · derivative.exercise_price: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

F3 · shares: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

F3 · price: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

F3 · derivative.exercise_date: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

F3 · derivative.expiration_date: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

Read SEC document
October 03, 2022 Filed Oct 3, 2022 20:25 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 Disposition to issuerCommon Shares 2,900 $148.50 $430,650.00
Disclosure

SEC source: 0001562180-22-006961 · primarydocument.xml · nonDerivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

F2 · price: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC Biohaven Ltd. BHVN · Entity 4379 GrantStock Options (Right to Buy) · Derivative 125,000 $0.00 Strike: $7.00 $0.00
Disclosure

SEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 13

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Shares · 125,000 shares

Expires 2032-10-04

F5 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC Biohaven Ltd. BHVN · Entity 4379 Exercise / conversionStock Options (Right to Buy) · Derivative 9,474 $0.00 Strike: $3.39 $0.00
Disclosure

SEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 12

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 9,474 shares

Expires 2030-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC Biohaven Ltd. BHVN · Entity 4379 Exercise / conversionStock Options (Right to Buy) · Derivative 5,998 $0.00 Strike: $3.56 $0.00
Disclosure

SEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 11

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 5,998 shares

Expires 2031-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC Biohaven Ltd. BHVN · Entity 4379 Exercise / conversionStock Options (Right to Buy) · Derivative 4,119 $0.00 Strike: $4.84 $0.00
Disclosure

SEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 10

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 4,119 shares

Expires 2032-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC Biohaven Ltd. BHVN · Entity 4379 OtherStock Options (Right to Buy) · Derivative 9,474 Not disclosed Strike: $3.39 Not disclosed
Disclosure

SEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 9

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,474

Underlying: Common Shares · 9,474 shares

Expires 2030-06-09

F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC Biohaven Ltd. BHVN · Entity 4379 OtherStock Options (Right to Buy) · Derivative 5,998 Not disclosed Strike: $3.56 Not disclosed
Disclosure

SEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 8

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,998

Underlying: Common Shares · 5,998 shares

Expires 2031-05-05

F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC Biohaven Ltd. BHVN · Entity 4379 OtherStock Options (Right to Buy) · Derivative 4,119 Not disclosed Strike: $4.84 Not disclosed
Disclosure

SEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 7

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,119

Underlying: Common Shares · 4,119 shares

Expires 2032-04-28

F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC Biohaven Ltd. BHVN · Entity 4379 Tax withholdingCommon Shares 3,263 $7.50 $24,472.50
Disclosure

SEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 6

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,486

F3 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC Biohaven Ltd. BHVN · Entity 4379 Exercise / conversionCommon Shares 9,474 $3.39 $32,116.86
Disclosure

SEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 5

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,749

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC Biohaven Ltd. BHVN · Entity 4379 Exercise / conversionCommon Shares 5,998 $3.56 $21,352.88
Disclosure

SEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 4

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,275

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC Biohaven Ltd. BHVN · Entity 4379 Exercise / conversionCommon Shares 4,119 $4.84 $19,935.96
Disclosure

SEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 3

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,277

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC Biohaven Ltd. BHVN · Entity 4379 OtherCommon Shares 1,708 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 2

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,158

F2 · shares: Effective as of the Distribution, each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares. As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:37 UTC Biohaven Ltd. BHVN · Entity 4379 OtherCommon Shares 1,450 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,450

F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer").

Read SEC document
October 03, 2022 Filed Oct 12, 2022 22:31 UTC Amendment Biohaven Ltd. BHVN · Entity 4379 Tax withholdingCommon Shares 12,959 $7.50 $97,192.50
Disclosure

SEC source: 0001562180-22-007175 · primarydocument.xml · nonDerivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,959

F1 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options.

F2 · shares: This amendment is being filed to correct the amount of shares beneficially owned reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that 3,263 shares were withheld by the Issuer in connection with the share settlement to cover the cost of the stock options; however, as reflected in this amendment, 9,790 shares were withheld by the Issuer in connect with the share settlement to cover the cost of the stock options. There were no other changes made to the information in the Original Form 4.

Read SEC document
May 19, 2022 Filed May 23, 2022 16:55 UTC Chubb Ltd CB · Entity 1639 GrantCommon Shares 1,594 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-031281 · doc4.xml · nonDerivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,346

F1 · kind: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.

F1 · price: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.

Read SEC document
April 28, 2022 Filed Apr 29, 2022 21:00 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GrantStock Option (Right to Buy) · Derivative 8,239 $0.00 Strike: $97.74 $0.00
Disclosure

SEC source: 0001562180-22-003585 · primarydocument.xml · derivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,239

Underlying: Common Shares · 8,239 shares

Expires 2032-04-27

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2023 or (b) the date of the 2023 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Read SEC document
December 20, 2021 Filed Dec 22, 2021 21:52 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GrantRestricted Share Unit Award · Derivative 3,417 $0.00 $0.00
Disclosure

SEC source: 0001562180-21-007870 · primarydocument.xml · derivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,417

Underlying: Common Shares · 3,417 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the issuer.

F1 · price: Each restricted share unit represents the contingent right to receive one common share of the issuer.

F2 · derivative.exercise_date: The reporting person was granted 3,417 restricted share units on December 20, 2021, which vested immediately upon grant. These restricted share units will settle on a deferred basis upon the reporting person's retirement from the Board of Directors of the issuer.

F3 · derivative.expiration_date: Not applicable.

Read SEC document
May 20, 2021 Filed May 24, 2021 18:32 UTC Chubb Ltd CB · Entity 1639 GrantCommon Shares 1,836 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-035243 · doc4.xml · nonDerivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,752

F1 · kind: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.

F1 · price: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.

Read SEC document
May 05, 2021 Filed May 7, 2021 16:33 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GrantStock Option (Right to Buy) · Derivative 11,996 $0.00 Strike: $71.94 $0.00
Disclosure

SEC source: 0001562180-21-003335 · primarydocument.xml · derivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,996

Underlying: Common Shares · 11,996 shares

Expires 2031-05-04

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 5, 2022 or (b) the date of the 2022 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Read SEC document
June 09, 2020 Filed Jun 12, 2020 17:58 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GrantStock Options (Right to buy) · Derivative 36,000 $0.00 Strike: $68.57 $0.00
Disclosure

SEC source: 0001562180-20-004470 · primarydocument.xml · derivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Shares · 36,000 shares

Expires 2030-06-09

F1 · derivative.exercise_date: This option grant was made pursuant to the issuer's non-employee director compensation policy. The common shares underlying this option vest in three equal installments on June 9, 2020, 2021, and 2022, subject to the reporting person's continuous service with the issuer at each vesting date.

Read SEC document
June 09, 2020 Filed Mar 26, 2021 16:14 UTC Amendment Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GrantStock Options (Right to buy) · Derivative 18,948 $0.00 Strike: $68.57 $0.00
Disclosure

SEC source: 0001562180-21-002442 · primarydocument.xml · derivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,948

Underlying: Common Shares · 18,948 shares

Expires 2030-06-09

F1 · shares: On June 12, 2020, the reporting person filed a Form 4 in respect of 36,000 options granted pursuant to the issuer's non-employee director compensation policy. The issuer subsequently determined that 17,052 of the options comprising such award were null and void upon grant as a result of the $1,000,000 annual limit for non-employee director compensation under its 2017 Equity Incentive Plan.

F2 · derivative.exercise_date: This option grant was made pursuant to the issuer's non-employee director compensation policy. The common shares underlying this option vest in three equal installments on June 9, 2021, 2022, and 2023, subject to the reporting person's continuous service with the issuer at each vesting date.

Read SEC document
May 20, 2020 Filed May 22, 2020 15:27 UTC Chubb Ltd CB · Entity 1639 GrantCommon Shares 2,916 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-031598 · doc4.xml · nonDerivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,916

F1 · kind: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.

F1 · price: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.

Read SEC document
May 08, 2020 Filed May 12, 2020 01:58 UTC Allergan plc AGN · Entity 149298 Disposition to issuerOrdinary Shares, par value $0.0001 4,294 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-012762 · doc4.xml · nonDerivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · balance_after: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.

Read SEC document
May 01, 2020 Filed May 5, 2020 00:55 UTC Allergan plc AGN · Entity 149298 Tax withholdingOrdinary Shares, par value $0.0001 2,064 $189.74 $391,623.36
Disclosure

SEC source: 0001179110-20-005444 · edgar.xml · nonDerivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,294

Read SEC document
May 02, 2019 Filed May 2, 2019 20:48 UTC Allergan plc AGN · Entity 149298 GrantOrdinary Shares, par value $0.0001 2,064 $145.33 $299,961.12
Disclosure

SEC source: 0001179110-19-005415 · edgar.xml · nonDerivative · entry 2

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,285

F2 · shares: These restricted stock units shall vest on the earlier of (i) the day before the 2020 Annual General Meeting of Shareholders and (ii) May 1, 2020.

F1 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

Read SEC document
April 30, 2019 Filed May 2, 2019 20:48 UTC Allergan plc AGN · Entity 149298 Tax withholdingOrdinary Shares, par value $0.0001 205 $147.00 $30,135.00
Disclosure

SEC source: 0001179110-19-005415 · edgar.xml · nonDerivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,221

F1 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

Read SEC document
February 18, 2019 Filed Feb 20, 2019 16:26 UTC Allergan plc AGN · Entity 149298 GrantOrdinary Shares, par value $0.0001 426 $139.07 $59,243.82
Disclosure

SEC source: 0001179110-19-002128 · edgar.xml · nonDerivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,426

F1 · shares: These restricted stock units shall vest on the earlier of (i) the day before the 2019 Annual General Meeting of Shareholders and (ii) May 2, 2019.

F2 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

Read SEC document
November 09, 2017 Filed Nov 13, 2017 18:18 UTC MEDICINES CO /DE MDCO · Entity 152552 Exercise / conversionStock Option (right-to-buy) · Derivative 12,039 Not disclosed Strike: $21.14 Not disclosed
Disclosure

SEC source: 0001179110-17-014063 · edgar.xml · derivative · entry 10

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,039 shares

Expires 2022-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: Not applicable

F5 · derivative.exercise_date: This option vested in one installment beginning on June 22, 2012.

Read SEC document
November 09, 2017 Filed Nov 13, 2017 18:18 UTC MEDICINES CO /DE MDCO · Entity 152552 Exercise / conversionStock Option (right-to-buy) · Derivative 13,259 Not disclosed Strike: $18.18 Not disclosed
Disclosure

SEC source: 0001179110-17-014063 · edgar.xml · derivative · entry 9

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,259 shares

Expires 2021-05-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: Not applicable

F4 · derivative.exercise_date: This option vested in one installment beginning on June 26, 2011.

Read SEC document
November 09, 2017 Filed Nov 13, 2017 18:18 UTC MEDICINES CO /DE MDCO · Entity 152552 Exercise / conversionStock Option (right-to-buy) · Derivative 7,500 Not disclosed Strike: $8.28 Not disclosed
Disclosure

SEC source: 0001179110-17-014063 · edgar.xml · derivative · entry 8

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,500 shares

Expires 2020-06-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: Not applicable

F3 · derivative.exercise_date: This option vested in twelve equal monthly installments beginning on July 2, 2010.

Read SEC document
November 09, 2017 Filed Nov 13, 2017 18:18 UTC MEDICINES CO /DE MDCO · Entity 152552 Exercise / conversionStock Option (right-to-buy) · Derivative 7,500 Not disclosed Strike: $7.51 Not disclosed
Disclosure

SEC source: 0001179110-17-014063 · edgar.xml · derivative · entry 7

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,500 shares

Expires 2019-05-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: Not applicable

F2 · derivative.exercise_date: This option vested in twelve equal monthly installments beginning on June 28, 2009.

Read SEC document
November 09, 2017 Filed Nov 13, 2017 18:18 UTC MEDICINES CO /DE MDCO · Entity 152552 Exercise / conversionStock Option (right-to-buy) · Derivative 7,500 Not disclosed Strike: $18.30 Not disclosed
Disclosure

SEC source: 0001179110-17-014063 · edgar.xml · derivative · entry 6

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,500 shares

Expires 2018-05-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: Not applicable

F1 · derivative.exercise_date: This option vested in twelve equal monthly installments beginning on June 29, 2008.

Read SEC document
November 09, 2017 Filed Nov 13, 2017 18:18 UTC MEDICINES CO /DE MDCO · Entity 152552 Exercise / conversionCommon Stock 12,039 $21.14 $254,504.46
Disclosure

SEC source: 0001179110-17-014063 · edgar.xml · nonDerivative · entry 5

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,431

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 09, 2017 Filed Nov 13, 2017 18:18 UTC MEDICINES CO /DE MDCO · Entity 152552 Exercise / conversionCommon Stock 13,259 $18.18 $241,048.62
Disclosure

SEC source: 0001179110-17-014063 · edgar.xml · nonDerivative · entry 4

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,392

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 09, 2017 Filed Nov 13, 2017 18:18 UTC MEDICINES CO /DE MDCO · Entity 152552 Exercise / conversionCommon Stock 7,500 $8.28 $62,100.00
Disclosure

SEC source: 0001179110-17-014063 · edgar.xml · nonDerivative · entry 3

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,133

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 09, 2017 Filed Nov 13, 2017 18:18 UTC MEDICINES CO /DE MDCO · Entity 152552 Exercise / conversionCommon Stock 7,500 $7.51 $56,325.00
Disclosure

SEC source: 0001179110-17-014063 · edgar.xml · nonDerivative · entry 2

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,633

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 09, 2017 Filed Nov 13, 2017 18:18 UTC MEDICINES CO /DE MDCO · Entity 152552 Exercise / conversionCommon Stock 7,500 $18.30 $137,250.00
Disclosure

SEC source: 0001179110-17-014063 · edgar.xml · nonDerivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,133

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.